ClinicalTrials.gg
RecruitingNCT06341517ATHENAUpdated Nov 19, 2024

Brain Circuitry Therapeutics for Schizophrenia

An interventional study of iTBS in Schizophrenia; Psychosis, sponsored by Indrit Begue. Recruiting at 2 sites in Switzerland. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-11-19.

Sponsored by Indrit Begue · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Schizophrenia with a site in Switzerland — 6 open to participants now, 6 under way, 1 of them phase 3. Schizophrenia · Switzerland.

Planned enrollment
19th of 27
70 · median 100
Started
2024
with 1 other
No phase
17 of 30
5 open now
Registered
28th of 30
by date
Lead sponsor
1 of 30
Indrit Begue

Among the 30 studies in Schizophrenia with a site in Switzerland, this one is the 19th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2024, is one of 17 with no phase, and was the 28th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 30 studies in Schizophrenia with a site in Switzerland are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Schizophrenia with a site in Switzerland, or all of them as a file.
02

Study summary

This project is a double blind randomized clinical trials that examines the efficacy of cerebellar non invasive stimulation for apathy improvement in patients with schizophrenia

Read the detailed description

This double-blind RCT aims to explore the efficacy of intensiveTranscranial Magnetic Stimulation (TMS) in schizophrenia spectrum disorders. Previous studies in various disorders suggest that intensive TMS is efficacious and safe.

Participants will undergo neuronavigated intermittent theta burst TMS, targeted to individual network targets, at an accelerated protocol (multiple sessions a day), The primary goal is to determine the efficacy of this protocol in alleviating negative symptoms of schizophrenia.

Additionally, the study will measure the impact of accelerated TMS on a range of clinical and cognitive outcomes, along with neuroimaging markers indicative of symptom response.

03

Conditions studied

  • Schizophrenia; Psychosis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Inclusion criteria

    • Capable of giving as evaluated by the treating psychiatrist
    • Informed Consent signed by the subject
    • Patients aged 18 - 65 years diagnosed with a schizophrenia spectrum disorder (including schizophrenia, schizoaffective or non-organic psychosis, psychotic disorder NOS) according to criteria
    • Clinically stable condition judged by their treating psychiatrist
    • Background antipsychotic medication treatments have remained unchanged for at least 4 weeks
    • No hospitalization in acute psychiatry ward at least 3 months prior to study entry

Specific exclusion criteria related to psychopathology

  • Comorbid and clinically active current major depressive episode determined by the treating psychiatrist.
  • Active psychotic symptoms. In particular, patients that at Baseline have a PANSS scores of more than 4 in any of the following PANSS items: delusions, suspiciousness/persecution and hallucinatory behaviour will be considered not stable enough to participate.
  • Significant extrapyramidal side-effects quantified by total score of mSAS > 12.
  • Increased sedation due to use of medication (slowing, drowsiness, slurred speech etc.)
  • Active daily use of substances (i.e. cocaine), including for therapeutically medical purposes (e.g., methadone substitution)

Exclusion criteria related to MRI or TMS

  • History of fainting spells of unknown or undetermined aetiology that might constitute seizures
  • History of multiple seizures or diagnosis of epilepsy
  • Any progressive (e.g., neurodegenerative) neurological disorder such as multiple sclerosis or Parkinson's disease
  • Chronic uncontrolled medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)
  • Metallic objects/implants (excluding dental fillings) unless cleared to be MRI compatible (i.e. MRI compatible joint replacement)
  • Any implants controlled by physiological signs in/near the head

    • Pacemaker
    • Implanted medication pump
    • Vagal nerve stimulator
    • Deep brain stimulator or TENS unit
    • Ventriculo-peritoneal shunt
    • Cochlear implant
  • Impaired ability to sense heat/pain, open wounds etc.
  • Increased intracranial pressure
  • Intracranial lesion, from a known genetic disorder or from acquired neurologic disease (e.g. stroke, tumor, cerebral palsy, severe head injury, or significant dysmorphology).
  • History of head injury resulting in prolonged loss of consciousness (>15minutes) or neurological sequelae
  • Ongoing pregnancy and breastfeeding. All participants capable of becoming pregnant will be required to have active ; any participant who is pregnant or breastfeeding will not be enrolled in the study.

Other exclusion criteria

  • concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, cancer, pulmonary decompensation etc.)
  • Inability to follow the procedures of the investigation, e.g. due to language problems, psychological disorders, intellectual retardation, dementia, etc. of the subject
  • Having legal obligation for psychiatric treatment.
  • Participation in another investigation with an drug or another MD within the 30 days preceding and during the present investigation.
  • Previous enrolment into the current investigation
  • Enrolment of the PI, his/her family members, employees and other dependent persons.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    Active

    Active intermittent theta burst stimulation (iTBS) to the cerebellum at 80% of active motor threshold.

    Device: iTBS

  • Placebo comparator
    Placebo

    Sham intermittent theta burst stimulation (iTBS) to the cerebellum

    Device: iTBS

Interventions

  • DeviceiTBS

    Intermittent Theta Burst Stimulation (iTBS) pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses for up to 8 sessions daily for 5 days

06

What researchers measure

Primary outcomes

  1. Brief Negative Symptoms Scale - apathy subscale (BNSS-Apathy) at follow-up (FU) at T3. The primary endpoint will be assessed at baseline and all follow-up visits at week 1, 6 and 12.

    This outcome measure focuses on the evaluation of changes in apathy symptoms in participants, utilizing the apathy subscale of the Brief Negative Symptoms Scale (BNSS-Apathy). Apathy symptoms will be assessed at baseline (pre-intervention) and subsequently at follow-up visits scheduled at weeks 1, 6, and 12 post-intervention. The primary endpoint of this measure is the change in BNSS-Apathy scores from baseline to each follow-up point, aiming to capture the trajectory of symptom changes across the study period. The BNSS-Apathy subscale score, derived from specific item responses, provides a quantitative measure of apathy severity, allowing for statistical analysis of symptom changes over time. Higher scores reflect greater severity of symptoms. Maximum score of BNSS-Apathy subscale score is 42 (severe apathy), minimum score is 0.

    Time frame: at 12 weeks

Secondary outcomes

  1. Positive and Negative Symptoms Scale (PANSS) positive and negative subscores at follow-up

    This outcome measure focuses on the evaluation of apathy and psychosis symptoms

    Time frame: at 1 week

  2. Positive and Negative Symptoms Scale (PANSS) positive and negative subscores at follow-up

    This outcome measure focuses on the evaluation of apathy and psychosis symptoms

    Time frame: at 6 weeks

  3. Positive and Negative Symptoms Scale (PANSS) positive and negative subscores at follow-up

    This outcome measure focuses on the evaluation of apathy and psychosis symptoms

    Time frame: at 12 weeks

  4. Self reported Negative Scale SNS scores and its sub-scales at follow-up

    This outcome measure focuses on the self-reported evaluation of apathy

    Time frame: at 1 week

  5. Self reported Negative Scale SNS scores and its sub-scales at follow-up

    This outcome measure focuses on the self-reported evaluation of apathy

    Time frame: at 6 weeks

  6. Self reported Negative Scale SNS scores and its sub-scales at follow-up

    This outcome measure focuses on the self-reported evaluation of apathy

    Time frame: at 12 weeks

  7. Brief neurocognitive assessment (BNA) scores at follow-up

    This outcome measure focuses on the evaluation of cognitive function

    Time frame: at 6 weeks

  8. Auditory Hallucinations Rating Scale (AHRS) scores at follow-up

    This outcome measure focuses on the evaluation of auditory hallucinations

    Time frame: at 6 weeks

  9. Calgary Depression Scale (CDSS) scores at follow-up

    This outcome measure focuses on the evaluation of depression symptoms

    Time frame: at 6 weeks

  10. Young Mania Rating Scale (YMRS) scores at follow-up

    This outcome measure focuses on the evaluation of mania symptoms

    Time frame: at 6 weeks

  11. Personal and social performance scale (PSP) scores at follow-up

    This outcome measure focuses on the evaluation of psychosocial functioning

    Time frame: at 12 weeks

  12. Deep-phenotyping outcome - sEBR (spontaneous eye blink)

    This outcome measure focuses on the evaluation of sEBR

    Time frame: at 6 weeks

  13. Deep-phenotyping outcome - facial expressions

    This outcome measure focuses on the evaluation of facial expressions

    Time frame: at 6 weeks

  14. Deep-phenotyping outcome - accelerometer

    This outcome measure focuses on the evaluation of accelerometry

    Time frame: at 6 weeks

  15. Cerebellar-cortical functional connectivity

    This outcome measure focuses on cerebellar-cortical functional connectivity

    Time frame: at 1 week

  16. Cerebellar-cortical structural connectivity

    This outcome measure focuses on cerebellar-cortical structural connectivity

    Time frame: at 6 weeks

  17. Cerebellar-cortical structural connectivity

    This outcome measure focuses on cerebellar-cortical structural connectivity

    Time frame: at 12 weeks

07

Study locations

1 of 2 sites recruiting
  • Campus Biotech
    Geneva, 1202, Switzerland
    Recruiting
  • Indrit Bègue
    Geneva, 1202, Switzerland
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Sep 2026, 29 months after the start.

Of 763 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 29 months is below that.

Counting every sponsor, half of 776 studies reached it within 32 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2023
First posted
Apr 2, 2024
StartActual
Apr 15, 2024
Primary completionEst.
Sep 25, 2026
CompletionEst.
Dec 12, 2027
Last update
Nov 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06341517
Lead sponsor
Indrit Begue
Collaborators
University of Geneva, Switzerland
Responsible party
Indrit Begue (Assistant Professor, University of Geneva, Switzerland) — Sponsor-investigator
First posted
Apr 2, 2024
Start date
Apr 15, 2024
Primary completion
Sep 25, 2026 (estimated)
Completion
Dec 12, 2027 (estimated)
Last update
Nov 19, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion